dentalblogs.com

dental news for dentists from the best minds in dentistry today

dentalblogs.com header image 2

Straumann Announces Regenerative Portfolio Product Updates at Key U.S. Dental Meeting

September 14th, 2009 · No Comments

Press Release…

  • First Straumann AlloGraft now available through agreement with LifeNet Health®
  • FDA approval supports new indication of Emdogain regenerative material for use with autograft, allograft, bone derived xenograft, ß-Tricalcium phosphate, and bioactive glass during bone graft procedures
  • Straumann introduces new developments at the American Academy of Periodontology 95th Annual Meeting at Booth # 801 this week in Boston

BOSTON (American Academy of Periodontology (AAP) 95th Annual
Meeting, Booth # 801) –September 12, 2009 – Straumann, a leader in
restorative, replacement and regenerative dentistry, today announced two new
developments to its regenerative product line: the addition of Straumann

AlloGraft, the company’s first allograft product for bone regeneration, and the
FDA approval of a new indication for Emdogain®, the company’s treatment for
periodontal regeneration. With these announcements, Straumann expands its
regenerative product portfolio to provide solutions for the various regenerative
treatment situations a clinician can encounter – from root to tooth.

Straumann AlloGraft

Straumann has formed a partnership with LifeNet Health®, a leading Organ
Procurement Organization (OPO) and one of the largest alloGraft bio-implant
providers in the country, to offer its first Allograft product—Straumann AlloGraft.

Now Straumann offers both allograft and fully synthetic bone graft substitutes for
bone regeneration procedures. Often dental implant placement is not possible
because the patient lacks adequate bone volume to support an implant, causing
practitioners to build up bone mass before placing an implant. Allograft and
synthetic bone augmentation material re-establish bone dimension enabling the
placement of dental implants in sites previously unsuitable for implant
procedures.

Straumann AlloGraft eliminates the need for patients to donate bone to
themselves, reducing the risk of additional complications associated with multiple
surgical sites. Straumann AlloGraft undergoes LifeNet Health’s proprietary and
patented Allowash XG® – the industry standard for allograft processing. LifeNet
has distributed over two million allografts since 1995 without a single recorded
infection transmission and has the longest continuous certification in the industry
from the American Association of Tissue Banks.

New Indication for Straumann Emdogain

Additionally, Straumann has received FDA approval of a new indication of
Emdogain, the company’s flagship regenerative product re-introduced to the
market last year. Emdogain can now be used with a variety of bone graft
materials, including autograft, allograft, bone-derived xenograft, beta-TCP or
bioactive glass in wide defects or where additional soft tissue support is needed.

This expanded use of Emdogain is supported by a consensus paper published
by the European Federation of Periodontists, which concluded that of the
treatment modalities researched only Emdogain alone or in combination with a
bone graft material had substantial published evidence. Straumann Emdogain is
a resorbable, injectable material that aids in the body’s natural ability to
regenerate the tissues (cementum, alveolar bone, and periodontal ligament)
responsible for tooth attachment when damaged by various forms of periodontal
disease.
“With these new regenerative offerings, Straumann continues its commitment to
providing dental professionals in the U.S. a range of treatment options as part of
a comprehensive portfolio of products for replacement, restorative and
regenerative dentistry,” said Martin Dymek, Regional Head North America. “The
addition of Straumann AlloGraft and the new indication for Emdogain promotes
choice and predictability for clinicians. Straumann’s commitment to produce
quality esthetic and reliable results is aimed at producing higher patient
satisfaction and ultimately, greater confidence for clinicians.”
Straumann will introduce both offerings at the American Academy of
Periodontology 95th Annual Meeting (AAP), held this week in Boston. At the
conference, Straumann Emdogain will also be featured in a presentation that
outlines the effectiveness of coronally advanced flaps with the use of Emdogain®
in the treatment of recession defects. This clinically-oriented lecture will blend
diagnostic guidelines and step-by-step techniques to provide a well-rounded
understanding regarding this treatment option and when it is indicated. Dr.
Michael McGuire, DDS will lead the presentation at the Straumann Corporate
Forum in Ballroom 210A.

Tags: Press Release

0 responses so far ↓

  • There are no comments yet...Kick things off by filling out the form below.

Leave a Comment